Caribou Biosciences to Highlight Vispa-cel and CB-011 Programs During Oral Presentations at the 2026 European Hematology Association (EHA) Annual Meeting
Caribou Biosciences announced that two abstracts detailing its vispa-cel and CB-011 programs have been accepted for oral presentations at the 2026 European Hematology Association Annual Meeting. The vispa-cel presentation will highlight long-term durability data from the ANTLER phase 1 trial in lymphoma, while the CB-011 presentation includes longer follow-up from the CaMMouflage phase 1 trial in multiple myeloma.
Key figures
- ANTLER patients treated
- 84
- Ca MMouflage patients treated
- 48
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.